for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TRACON Pharmaceuticals Inc

TCON.OQ

Latest Trade

0.47USD

Change

0.01(+2.22%)

Volume

30,909

Today's Range

0.45

 - 

0.47

52 Week Range

0.40

 - 

2.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.46
Open
0.45
Volume
30,909
3M AVG Volume
4.00
Today's High
0.47
Today's Low
0.45
52 Week High
2.33
52 Week Low
0.40
Shares Out (MIL)
29.94
Market Cap (MIL)
13.77
Forward P/E
-0.53
Dividend (Yield %)
--

Next Event

Q3 2019 TRACON Pharmaceuticals Inc Earnings Release

Latest Developments

More

Tracon Pharmaceuticals Says Qtrly Loss Per Share $0.21

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253

Tracon Pharmaceuticals Reports Qtrly Loss Per Share $0.24

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry

Biotechnology & Drugs

Contact Info

4350 La Jolla Village Dr Ste 800

+1.858.5500780

http://www.traconpharma.com/

Executive Leadership

Charles P. Theuer

President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director

Mark C. Wiggins

Chief Business Officer

William R. LaRue

Independent Director

Martin A. Mattingly

Independent Director

J. Rainer Twiford

Independent Director

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.130

2017

-1.140

2018

-1.300

2019(E)

-0.873
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
73.92
LT Debt To Equity (MRQ)
45.49
Return on Investment (TTM)
-105.49
Return on Equity (TTM)
-73.32

Latest News

BRIEF-Tracon Pharmaceuticals Files For Offering Of Up To 27.4 Mln Shares Of Common Stock By The Selling Stockholders

* TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 27.4 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS Source text: [https://bit.ly/2KQef7f] Further company coverage:

BRIEF-TRACON Pharmaceuticals Reports Qtrly Loss Per Share $0.46

* TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Tracon Pharmaceuticals Says Patricia Bitar Notified That Resigning As Co's CFO

* TRACON PHARMACEUTICALS INC - ON APRIL 30, PATRICIA L. BITAR NOTIFIED THAT RESIGNING AS CO'S CFO, EFFECTIVE JUNE 15, 2018- SEC FILING Source text for Eikon: (https://bit.ly/2w9w9yD) Further company coverage:

BRIEF-Tracon Pharmaceuticals Says Regarding Election Of Ted Wang To Board, Board Approved Increase In Size From Six To Seven Members

* TRACON PHARMACEUTICALS SAYS REGARDING ELECTION OF TED WANG TO BOARD, BOARD APPROVED AN INCREASE IN SIZE FROM SIX TO SEVEN MEMBERS - SEC FILING Source text: (https://bit.ly/2JBtjFa) Further company coverage:

BRIEF-Linden Capital Reports 9.9 Pct Passive Stake In Tracon Pharmaceuticals

* LINDEN CAPITAL L.P. REPORTS 9.9 PCT PASSIVE STAKE IN TRACON PHARMACEUTICALS INC AS OF MARCH 27, 2018 - SEC FILING Source text: [https://bit.ly/2pZqDIp] Further company coverage:

BRIEF-TRACON Pharmaceuticals Announces $38.7 Million Private Placement

* TRACON PHARMACEUTICALS ANNOUNCES $38.7 MILLION PRIVATE PLACEMENT

BRIEF-TRACON Pharma Qtrly Loss Per Share $0.37

* TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China

* AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget

BRIEF-Tracon Pharma reports third quarter financial results

* Tracon Pharmaceuticals reports third quarter financial results and provides corporate update

BRIEF-683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals

* 683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing Source text: [http://bit.ly/2yb8Zbn] Further company coverage:

BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma

* Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B Traxar study of TRC105 and Inlyta in renal cell carcinoma

BRIEF-Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock

* Files for offering of up to $14.33 million of co's common stock - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Tracon Pharmaceuticals announces positive results for phase 1/2 trial of TRC105 and Nexavar

* Tracon Pharmaceuticals announces positive results from National Cancer Institute Phase 1/2 trial of TRC105 and Nexavar in Hepatocellular cancer published in Clinical Cancer Research

BRIEF-Tracon Pharmaceuticals qtrly net loss per share $0.40

* Tracon Pharmaceuticals reports second quarter financial results and provides corporate update

BRIEF-Santen and Tracon announce initiation of a phase 2a study of drug for the treatment of wet age-related macular degeneration

* Santen and Tracon announce initiation of a phase 2a study of DE-122 for the treatment of wet age-related macular degeneration

BRIEF-Tracon Pharmaceuticals reports collaboration revenue $626,000

* Tracon Pharmaceuticals reports first quarter financial results and provides corporate update

BRIEF-Tracon Pharmaceuticals files for sale of up to 3.23 mln shares of co's common stock by Aspire Capital Fund LLC - SEC filing

* Tracon Pharmaceuticals Inc - files for sale of up to 3.23 million shares of co's common stock by Aspire Capital Fund LLC - SEC filing

BRIEF-Tracon Pharmaceuticals announces $21 mln common stock purchase agreement with Aspire Capital Fund

* Tracon Pharmaceuticals announces $21 million common stock purchase agreement with Aspire Capital Fund, LLC

BRIEF-Tracon Pharmaceuticals announces first patient dosed in phase 3 TAPPAS trial

* Tracon Pharmaceuticals announces first patient dosed in phase 3 tappas trial of TRC105 in angiosarcoma Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up